Imidazopyridine derivatives as modulators of TNF activity
US9309243B2 · kind B2 · utility
3Cited by
1References
11Claims
0Family size
Assignee
Inventors
- Jonathan Mark Bentley
- Daniel Christopher Brookings
- Julien Alistair Brown
- Thomas Paul Cain
- Praful Tulshi Chovatia
- Anne Marie Foley
- Ellen Olivia Gallimore
- Laura Gleave
- Alexander Heifetz
- Helen Tracey Horsley
- Martin Clive Hutchings
- Victoria Elizabeth Jackson
- James A. Johnson
- Craig Johnstone
- Boris Kroeplien
- Fabien Claude Lecomte
- Deborah Leigh
- Martin Alexander Lowe
- James Madden
- John Robert Porter
- Joanna Rachel Quincey
- Laura Claire Reed
- James Thomas Reuberson
- Anthony Richardson
- Sarah Emily Richardson
- Matthew Duncan Selby
- Michael Alan Shaw
- Zhaoning Zhu
Key dates
| Filing date | Jul 5, 2013 |
| Grant date | Apr 12, 2016 |
| Priority date | — |
| Expiry date | Jul 5, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.